BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

488 related articles for article (PubMed ID: 11862469)

  • 1. Comparison of interleukin-12 with lung cancer and malignant lymphoma undergoing autologous peripheral blood stem cell transplantation.
    Yoshimura C; Nomura S; Kanazawa S; Kuwana M; Yamaguchi K; Fukuhara S
    J Cancer Res Clin Oncol; 2002 Jan; 128(1):29-36. PubMed ID: 11862469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in the T-helper cell 1/T-helper cell 2 balance of peripheral T-helper cells after autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma.
    Mukai M; Bohgaki T; Kondo M; Notoya A; Kohno M
    Ann Hematol; 2001 Dec; 80(12):715-21. PubMed ID: 11797111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autologous stem cell transplantation: sequential production of hematopoietic cytokines underlying granulocyte recovery.
    Baiocchi G; Scambia G; Benedetti P; Menichella G; Testa U; Pierelli L; Martucci R; Foddai ML; Bizzi B; Mancuso S
    Cancer Res; 1993 Mar; 53(6):1297-303. PubMed ID: 7680283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time-course of the recovery of cellular immune function after high-dose chemotherapy and peripheral blood progenitor cell transplantation for high-grade non-Hodgkin's lymphoma.
    Scheid C; Pettengell R; Ghielmini M; Radford JA; Morgenstern GR; Stern PL; Crowther D
    Bone Marrow Transplant; 1995 Jun; 15(6):901-6. PubMed ID: 7581089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma.
    Schmitz N; Kloess M; Reiser M; Berdel WE; Metzner B; Dorken B; Kneba M; Trumper L; Loeffler M; Pfreundschuh M; Glass B;
    Cancer; 2006 Jan; 106(1):136-45. PubMed ID: 16331635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural killer cell numbers and activity in mobilized peripheral blood stem cell grafts: conditions for in vitro expansion.
    Silva MR; Parreira A; Ascensão JL
    Exp Hematol; 1995 Dec; 23(14):1676-81. PubMed ID: 8542964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intracellular IL-4/IFN-gamma producing peripheral T lymphocyte subsets in B cell non-Hodgkin's lymphoma patients.
    Gergely L; Aleksza M; Váróczy L; Ponyi A; Sipka S; Illés A; Szegedi G
    Eur J Haematol; 2004 May; 72(5):336-41. PubMed ID: 15059068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes of immunological markers after autologous peripheral blood stem cell transplantation.
    Katsura K; Nomura S; Ohtani T; Matsumoto N; Shimizu T; Yamaguchi K; Kishimoto Y; Kitajima H; Fukuhara S
    J Cancer Res Clin Oncol; 1998; 124(11):633-40. PubMed ID: 9860293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autologous peripheral blood stem cell transplantation and adoptive immunotherapy with activated natural killer cells in the immediate posttransplant period.
    Lister J; Rybka WB; Donnenberg AD; deMagalhaes-Silverman M; Pincus SM; Bloom EJ; Elder EM; Ball ED; Whiteside TL
    Clin Cancer Res; 1995 Jun; 1(6):607-14. PubMed ID: 9816022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A patient with mantle cell lymphoma who successfully underwent auto-PBSCT in combination with in vivo purging of tumor cells using rituximab].
    Kanaji N; Ishibashi K; Uno H; Hino N
    Gan To Kagaku Ryoho; 2002 Dec; 29(13):2569-72. PubMed ID: 12506485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment and characterization of the cytolytic T lymphocyte response against Epstein-Barr virus in patients with non-Hodgkin's lymphoma after autologous peripheral blood stem cell transplantation.
    Nolte A; Buhmann R; Straka C; Emmerich B; Hallek M
    Bone Marrow Transplant; 1998 May; 21(9):909-16. PubMed ID: 9613783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombopoietin levels in patients undergoing autologous peripheral blood stem cell transplantation.
    Yoshimura C; Nomura S; Katsura K; Yamaguchi K; Fukuhara S
    Vox Sang; 2000; 78(2):106-12. PubMed ID: 10765146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of high-dose chemotherapy with subsequent transplantation of blood-forming cells on left ventricle function in patients with malignant lymphomas treated with doxorubicin in primary chemotherapy].
    Elbl L; Vásová I; Krejcí M; Navrátil M; Tomásková I; Jedlicka F; Chaloupka V; Mayer J; Vorlícek J
    Vnitr Lek; 2006 Mar; 52(3):221-31. PubMed ID: 16722153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and immunomodulatory effects of combination immunotherapy with low-dose interleukin 2 and tumor necrosis factor alpha in patients with advanced non-small cell lung cancer: a phase I trial.
    Yang SC; Grimm EA; Parkinson DR; Carinhas J; Fry KD; Mendiguren-Rodriguez A; Licciardello J; Owen-Schaub LB; Hong WK; Roth JA
    Cancer Res; 1991 Jul; 51(14):3669-76. PubMed ID: 1648441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.
    Miller JS; Tessmer-Tuck J; Pierson BA; Weisdorf D; McGlave P; Blazar BR; Katsanis E; Verfaillie C; Lebkowski J; Radford J; Burns LJ
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):34-44. PubMed ID: 9209739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Defective cytokine production following autologous stem cell transplantation for solid tumors and hematologic malignancies regardless of bone marrow or peripheral origin and lack of evidence for a role for interleukin-10 in delayed immune reconstitution.
    Guillaume T; Sekhavat M; Rubinstein DB; Hamdan O; Leblanc P; Symann ML
    Cancer Res; 1994 Jul; 54(14):3800-7. PubMed ID: 7913409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Angioimmunoblastic T-cell lymphoma occurring four months after autologous peripheral blood stem cell transplantation with high-dose chemotherapy for follicular lymphoma].
    Miyazaki K; Masuya M; Yamaguchi M; Isaka S; Nakase K; Kobayashi T; Nakamura S; Shiku H
    Rinsho Ketsueki; 2005 Sep; 46(9):1065-70. PubMed ID: 16440766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment of disseminated nasal T-cell lymphoma using high-dose chemotherapy and autologus peripheral blood stem cell transplantation: a case report.
    Kouzaki H; Kitanishi T; Kitano H; Suzuki M
    Auris Nasus Larynx; 2004 Mar; 31(1):79-83. PubMed ID: 15041059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid immunologic reconstitution following transplantation with mobilized peripheral blood stem cells as compared to bone marrow.
    Talmadge JE; Reed E; Ino K; Kessinger A; Kuszynski C; Heimann D; Varney M; Jackson J; Vose JM; Bierman PJ
    Bone Marrow Transplant; 1997 Jan; 19(2):161-72. PubMed ID: 9116614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.